Skip to main content
. Author manuscript; available in PMC: 2014 Oct 30.
Published in final edited form as: Adv Ophthalmol Vis Syst. 2014 Aug 27;1(2):00007. doi: 10.15406/aovs.2014.01.00007

Table 1.

Characterization of ganciclovir (GCV) lipid prodrugs.

Drug/Prodrug R1 R2 %Yield Theoretical Molecular Weight Observed [M+1]+ or [M+Na]+ Melting Point (°C) Clog P % Purity
Ganciclovir* H H - 255.1 256.2 250-252 -0.03 99.5*
GCV-mono-C5 n-C4H9CO H 19 339.35 340.5 224-226 -0.1 97.5
GCV-di-C5 n-C4H9CO n-C4H9CO 78 423.21 424.5 220-222 1.61 99.0
GCV-mono-C10 n-C9H19CO H 27 409.48 410.5 216-218 1.98 98.0
GCV-di-C10 n-C9H19CO n-C9H19CO 70 563.73 564.7 198-200 5.79 98.5
GCV-mono-C13 n-C12H25CO H 23 451.56 452.4 212-214 3.24 99.5
GCV-di-C13 n-C12H25CO n-C12H25CO 74 647.89 648.9 166-168 5.84 99.0
*

Ganciclovir (GCV) purity as reported by the manufacturer (Hubei Gedian Human well Pharmaceutical Co., Ltd. China)